Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbott Laboratories ( (ABT) ) just unveiled an update.
On March 9, 2026, Abbott Laboratories completed a $20 billion multi-tranche senior notes offering, issuing floating-rate and fixed-rate debt with maturities ranging from 2029 to 2066 through a syndicate led by major global underwriters. The notes were issued under an existing shelf registration and represent one of the company’s largest capital markets financings.
Abbott plans to use the net proceeds, along with cash on hand and potential additional borrowings, to fund the planned acquisition of Exact Sciences Corporation, refinance certain Exact Sciences indebtedness, pay related transaction costs and support general corporate purposes. If the Exact Sciences deal is not completed by a specified deadline or is formally abandoned, Abbott will be required to redeem the outstanding notes at 101% of principal plus accrued interest, adding a protective feature for bond investors around the transaction risk.
The most recent analyst rating on (ABT) stock is a Buy with a $127.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.
Spark’s Take on ABT Stock
According to Spark, TipRanks’ AI Analyst, ABT is a Neutral.
The score is driven primarily by solid financial performance (notably strong free cash flow) and a constructive earnings outlook with margin expansion and strong Devices/CGM momentum. Offsetting factors include weaker technical positioning versus longer-term moving averages, a premium valuation, and elevated uncertainty from earnings volatility and incomplete 2025 balance sheet data.
To see Spark’s full report on ABT stock, click here.
More about Abbott Laboratories
Abbott Laboratories is a diversified global health care company that develops, manufactures and markets medical devices, diagnostics, branded generic pharmaceuticals and nutritional products. The company targets hospitals, laboratories, physicians and consumers worldwide, focusing on long-term growth in diagnostics, medical devices and related health technologies.
Average Trading Volume: 9,371,630
Technical Sentiment Signal: Sell
Current Market Cap: $190.4B
See more data about ABT stock on TipRanks’ Stock Analysis page.